Kate Goodwin
Life Sciences Writer at BioSpace
christian. wife. mom. novelist. pharma news journalist. home buyer. renovator. professional mover. big talker. bigger dreams. indie author.
Articles
-
3 weeks ago |
architectureau.com | Kate Goodwin
On the shores of Gadigal waters in Sydney’s Woolloomooloo, the enchanting sound of a karanga – a Māori women’s spiritual call – fills the lobby of Artspace, welcoming visitors to Re-Stor(y)ing Oceania. The call sets the intention for the exhibition, which seeks to reconceptualise humanity’s relationship to the planet’s largest body of water at a time of an ecological, and arguably existential, crisis.
-
1 month ago |
biospace.com | Kate Goodwin
Breakthroughs in gene editing coupled with the next generation of anti-CD40L antibodies could help enable xenotransplantation—the transplantation of animal organs or tissues into humans—and provide a gateway to solving a major global health crisis: a shortage of donor organs. Each day, 20 people in the U.S. die waiting for an organ transplant.
-
1 month ago |
biospace.com | Kate Goodwin
The rise of GLP-1 receptor agonists has changed the therapeutic weight loss industry forever. Now, as more companies jostle to join the lucrative market, touting the highest percentage weight loss may take a back seat to a different competitive edge: overall health outcomes. Certainly, the efficacy the market leaders boast has generated unprecedented demand.
-
1 month ago |
biospace.com | Kate Goodwin
When GLP-1 drugs recently became a trendy talking point for their impressive weight loss efficacy, their less-than-appealing aspects also came into focus, particularly gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation and abdominal pain are all commonly reported by people dropping pounds with Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide).
-
1 month ago |
biospace.com | Kate Goodwin
The legal battle continues between the FDA and compounding pharmacies over the latter party’s ability to produce blockbuster weight loss drugs such as semaglutide—marketed by Novo Nordisk as Wegovy—and tirzepatide—marketed by Eli Lilly has Zepbound. Following the removal of these drugs from the FDA shortage list, the compounders trade group Outsourcing Facilities Association (OFA) filed lawsuits in an attempt to continue making the lucrative drugs.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 275
- Tweets
- 410
- DMs Open
- No
If you love to read stories with these elements, check out my novel on Amazon and KU! https://t.co/sPetBfztA0 #WriterCommunity #book #romancebooks #RomanceReaders #MYSTERY https://t.co/CAO8dFluWu
#indieauthors help me out! Ready to #selfpublish my book through Amazon KDP and I’m torn on the ISBN thing. Do I need to buy one? I’ll be pretty happy/lucky just to sell my #debutnovel on Amazon, and am doubtful I’d get the chance to sell it elsewhere… How vital is it?
Some inspiration for that inside jacket author photo for my fellow #writersoftwitter 😉😂 #WritingCommunity https://t.co/cciG0TVPWg